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Despite cannabidiol (CBD) having numerous cardiovascular effects in vitro, its
haemodynamic effects in vivo are unclear. Nonetheless, the clinical use of CBD (Epidiolex)
is becoming more widespread. The aim of this systematic review was to establish
whether CBD is associated with changes in haemodynamics in vivo. Twenty-five studies
that assessed the haemodynamic effects of CBD (from PubMed, Medline and EMBASE)
were systematically reviewed and meta-analyzed. Data on blood pressure (BP), heart
rate (HR), and blood flow (BF) were extracted and analyzed using random effects models.
Twenty-two publications assessed BP and HR among 6 species (BP n = 344 and HR
n = 395), and 5 publications assessed BF in 3 species (n = 56) after acute dosing of
CBD. Chronic dosing was assessed in 4 publications in 3 species (total subjects BP,
n = 6; HR, n = 27; BF, n = 3). Acute CBD dosing had no effect on BP or HR under
control conditions. Similarly, chronic dosing with CBD had no effect on HR. In models
of stress, acute CBD administration significantly reduced the increase in BP and HR
induced by stress (BP, mean difference (MD) −3.54, 95% CI −5.19, −1.9, p < 0.0001;
HR, MD −16.23, 95% CI −26.44, −6.02, p = 0.002). In mouse models of stroke, CBD
significantly increased cerebral blood flow (CBF, standardized mean difference (SMD)
1.62, 95% CI 0.41, 2.83, p = 0.009). Heterogeneity among the studies was present,
there was no publication bias except in HR of control and stressful conditions after acute
CBD dosing, and median study quality was 5 out of 9 (ranging from 1 to 8). From the
limited data available, we conclude that acute and chronic administration of CBD had
no effect on BP or HR under control conditions, but reduces BP and HR in stressful
conditions, and increases cerebral blood flow (CBF) in mouse models of stroke. Further
studies are required to fully understand the potential haemodynamic effects of CBD in
humans under normal and pathological conditions.
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INTRODUCTION
Cannabidiol (CBD) is the second most abundant phytocannabinoid, after 19-
tetrahydrocannabinol (THC) (Pertwee, 2006; Tambaro and Bortolato, 2012) and was first
isolated from the cannabis extract in 1940 (Adams et al., 1940). The pharmacological actions of
CBD are complex; CBD has a low affinity to the cannabinoid receptor 1 (CB1) and cannabinoid
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receptor 2 (CB2) (Thomas et al., 2007; Pertwee, 2008), and targets
a wide range of other receptors including 5-hydroxytryptamine
(5-HT1a), transient receptor potential vanilloid receptor
1 (TRPV1), peroxisome proliferator-activated receptors
(PPARs) and G protein-coupled receptor 55 (GPR55) (Pertwee,
2008; Stanley et al., 2013a). It is suggested that CBD may
have therapeutic effects in a variety of disorders including
diabetes, gastrointestinal disturbances, cancer, oxidative stress,
inflammation and in cardiovascular disease (Russo and Guy,
2006; Capasso et al., 2008; Zuardi, 2008; Iuvone et al., 2009;
Booz, 2011). CBD may also have desirable effects in multiple
neurological and psychological disorders, including dystonia,
schizophrenia, epilepsy and Parkinson’s disease (Consroe et al.,
1986; Leweke et al., 2012; Chagas et al., 2014; Devinsky et al.,
2016). In a recent open-label trial investigating the effects of
CBD (Epidiolex, 2–50 mg/kg) on 214 young patients with
treatment-resistant epilepsy, CBD reduced seizure frequency
and demonstrated an acceptable safety profile (Devinsky et al.,
2016). Epidiolex was also safe and well tolerated in refractory
epilepsy secondary to tuberous sclerosis and for epileptic spasms,
highlighting its potential as a new treatment for refractory
epilepsy (Abati et al., 2015; Geffrey et al., 2015).
Pre-clinical studies on the effects of CBD on the
cardiovascular system have shown that CBD causes endothelium-
and nitric oxide-dependent vasorelaxation of isolated human
mesenteric arteries (Stanley et al., 2015) and PPARγ-dependent
vasorelaxation of the rat aorta (O’Sullivan et al., 2009). CBD
also improves vasorelaxation in the femoral arteries of Zucker
diabetic fatty rats via enhanced production of vasodilator
COX-1/2-derived products acting at EP4 receptors (Stanley
et al., 2013b; Wheal et al., 2014). CBD also decreases myocardial
infract size in a rat model of ischaemia/reperfusion injury
(Durst et al., 2007), attenuates myocardial dysfunction and
inflammation in an animal model of diabetes (Rajesh et al.,
2007), and attenuates inflammatory and oxidative stress changes
induced by high glucose in human coronary artery cells (Rajesh
et al., 2010). CBD also reduces cerebral vascular inflammation
and associated dilatation induced by lipopolysaccharide in mice
(Ruiz-Valdepenas et al., 2011), infarct size in animal models of
stroke (England et al., 2015) and reduced blood brain barrier
permeability (Hind et al., 2016). These effects on the cerebral
vasculature appear to involve 5HT1A and PPARγ. Together,
these pre-clinical studies might suggest that the cardiovascular
system is a therapeutic target for CBD (Stanley et al., 2013a).
However, despite these many vascular effects of CBD, it is not yet
clear whether CBD administration alters haemodynamics under
control or pathological situations.
Given the increasing clinical use of CBD, and the numerous
effects of CBD in the cardiovascular system, the aim of the
present study was to systematically review and analyse in
vivo studies evaluating the effects of CBD on alterations in
haemodynamics.
MATERIALS AND METHODS
Search Strategy
All studies potentially investigating the haemodynamic effect
of CBD (including BP, HR, and BF) were searched (until
November 2016) in Medline, EMBASE, and PubMed. Search
keywords included: Cannabidiol, Epidiolex, cardiovascular,
blood pressure (BP), systolic, diastolic, hypertension,
hypotension, heart rate (HR), tachycardia, bradycardia,
blood flow (BF), haemodynamic, vasodilatation, vasorelaxation,
and vasoconstriction. References from included studies were
also hand searched. Initially, the National Institute for Health
and Excellent Care platform was used in which two databases
(EMBASE and Medline) were used for searching. Then, a
separate search was conducted using PubMed. Pre-specified
inclusion and exclusion criteria were used to prevent bias;
studies had to be in vivo, assess haemodynamics (BP, HR,
or BF), be original articles, and be a controlled study. The
exclusion criteria were: in vitro studies, mixtures of CBD with
other cannabis extracts, studies not assessing haemodynamics
(BP, HR, or BF), review articles and editorials, or uncontrolled
studies.
Data Acquisition
Data on BP, HR, and BF were extracted from the included papers,
and the changes in haemodynamics at 2 h post-drug after acute
CBD dosing were used for analysis. A standardized time point of
2 h was decided as this was commonly available throughout the
articles and CBD has been previously shown to peak at 2 h in
plasma (Nadulski et al., 2005a,b). If there were no measurements
taken at this time point (2 h post-drug) the closest time point
to 2 h was used for analysis. In chronic studies, the mean of
total measurements or measurements taken at the end of the
study were used for analysis depending on data provided. If
the exact number of animals used in each drug group were not
available, the authors were contacted. If the authors were not
able to provide the necessary information, the lowest number of
animals within the range given was used for the experimental
group CBD, and the highest number was used for the control
group. If a crossover design was used in a study, the total number
of humans was distributed equally to the drug groups. Grab
application (version 1.5) was used to extract values from figures
given in published articles if no values were stated within the
text. If published articles used multiple groups (e.g., to assess
dose-dependent effects) with one control group, then the number
of humans or animals per control group was divided into the
number of comparison groups. For the dose-response analysis,
the total dose of the drug administrated to species up to the time
in which the haemodynamics were measured was used.
Quality
The methodological quality was assessed to identify risk of bias
using six-point criteria derived from the Cochrane collaborations
tool for assessing risk of bias (Higgins et al., 2011) and Stroke
Therapy Academic Industry Recommendations (STAIR) (Stroke
Therapy Academic Industry Roundtable, 1999). Each of the
following criteria was equal to 1 point: randomisation, allocation
concealment, blinding of outcome assessment, blinding of
personnel and participant, assessment ofmore than one outcome,
dose-response relationship, therapeutic time window, assessment
of outcome>24 h and incomplete outcome data.
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Data Analysis
Studies were divided into two groups (i.e., acute and chronic).
Data were grouped before analysis according to model (non-
stress and stress), and then sub-grouped by species (human,
mice, rats, etc.). For the CBD dose-response analysis, data were
grouped according to endpoint (BP, HR, or BF), and then sub-
grouped according to dose. Data from each group were analyzed
as forest plots using the Cochrane Review Manager software
(Version 5.3. Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014), and as funnel plots using Stata
(StataCorp. 2009. Stata Statistical Software: Release 11. College
Station, TX, USA). Funnel plot asymmetry (publication bias) was
tested by Egger’s test (Egger et al., 1997). Stata was also used
for meta-regression that described the relationship between CBD
dose and effect size. PRISM 7 (GraphPad, Software, La Jolla,
CA, USA) was used to produce figures of dose-response. Since
heterogeneity was expected between study protocols (different
species, models, dose and time) random-effect models were used.
The results of continuous data on BP and HR are expressed as
mean difference (MD), and as standardized mean difference on
BF with 95% confidence intervals (CIs) due to the different scales
used in assessing BF. Studies were weighted by sample size and
statistical significance was set at p< 0.05.
RESULTS
From the initial 1016 search results, 277 relevant publications
were identified from three databases (Medline, EMBASE, and
PubMed). Of these, 25 articles met the inclusion criteria (see
Figure 1). A summary of the data extracted from included studies
is shown in Table 1.
Blood Pressure and Heart Rate
Ten publications assessed the acute effect of CBD administration
on BP, and 15 publications assessed the effect of CBD
administration on HR in 5 species, including humans, mice,
FIGURE 1 | Flow chart for study retrieval and selection. In vitro studies, interaction studies including mixtures of CBD with other cannabis extracts, studies not
assessing haemodynamics (BP, HR, or BF), review articles and editorials, or uncontrolled studies were excluded.
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TABLE 1 | Summary of included studies in chronological order.
Reference Species Model Dose (CBD) Route Time of CBD
administration
Time of haemodynamic
measurements
Finding
Borgen and Davis,
1974
Rabbits Anaesthetised 25 mg/kg i.v. Pre-test Pre-drug and hourly interval to
7 h post-drug
No changes on
HR
Bright et al., 1975 Dogs Anaesthetised 0.5 or 1 mg/kg i.v. Pre-test During 30 min post-drug. ↑MBP and HR
Belgrave et al.,
1979
Humans Healthy
volunteers
320 µg/kg Oral Pre-test Pre-drug and at 1.5, 2.5 and
3.5 h post-drug
No changes on
HR
Gong et al., 1984 Human Healthy
volunteers
100, 600 or
1200mg
Oral Pre-test Hourly interval to 6 h post-dru No changes on
SBP, DBP or HR
1200mg Pre-test Hourly interval to 6 h
post-drug
1200mg Single dose per day for
20 days
Hourly interval to 6 h
post-drug and on days 5, 12
and 19
Consroe et al.,
1991
Human Patients with
Huntington
disease
10 mg/kg Oral Single dose per day for
6 weeks
Pre-drug, during and
post-drug
No changes on
MBP or HR
Zuardi et al., 1993 Human Healthy
volunteers
300mg Oral Pre-test Pre-drug and Post drug at 80
min (pre-stress), 85 min
(during stress) and 100 min
(post-stress)
No changes on
SBP or HR
Mishima et al.,
2005
Mice MCAO 3 mg/kg i.p. Pre and 3 h
post-occlusion
MBP and HR: 2 h
post-occlusion
No changes on
MBP or HR
CBF: during 4 h
post-occlusion
↑CBF
Resstel et al.,
2006
Rats Stress (fear) 10 mg/kg i.p. Pre-test Pre-stress and during 10 min
post-stress
↓MBP and HR
post-stress
Hayakawa et al.,
2007a
Mice MCAO 3 mg/kg i.p. Pre, 3 and 4 h
post-occlusion, and 1
and 2 h post-reperfusion
MBP and HR: pre-reperfusio No changes on
MBP or HR
CBF: during 4 h of occlusion
and post-reperfusion
↑CBF
Hayakawa et al.,
2007b
Mice MCAO 3 mg/kg i.p. Pre-occlusion and 3 h
post-occlusion and
Single dose per day for
14 days
During 4 h and on day 14
post-occlusion
↑CBF
Durst et al., 2007 Rats Myocardial
infarction
5 mg/kg for 7 days i.p. Pre-ischaemia and
post-ischaemia for 7
days
On day 1 and 7
post-ischaemia
No changes on
HR
Alvarez et al., 2008 Piglets Carotid
occlusion and
hypoxic
ischaemia
0.1 mg/kg i.v. 15 min and 4 h
post-procedure
MBP and HR: pre-procedure
and at 3 and 6 h
post-procedure
Maintain MBP
and HR after the
fall post- hypoxic
ischaemia
CBF: pre-procedure and
during 6 h post-procedure
↑CBF
Hayakawa et al.,
2008
Mice MCAO 3 mg/kg i.p. Pre-occlusion and 3 h
post-occlusion
During 4 h post-occlusion No changes on
MBP or HR
Resstel et al.,
2009
Rats Stress (restraint) 1, 10, or 20 mg/kg i.p. Pre-stress Pre-stress and during 1 hr
post-stress
↓MBP and HR
post-stress
Alves et al., 2010 Rats Conscious 60 nmol BNST Post-ACSF During 60 min post-drug No changes on
MBP or HR
Walsh et al., 2010 Rats Myocardial
infarction
10 or 50 µg/kg i.v. Pre-ischaemia and
pre-reperfusion
Pre- ischaemia during 2.30 h
post-ischaemia,
↓MBP
Granjeiro et al.,
2011
Rats Stress (restraint) 15, 30 or 60 nmol intracisternal Pre-stress Pre-stress and during 1 hr
post-stress
No change in
MBP or HR
Hallak et al., 2011 Human Healthy
volunteers
600mg Oral Pre-test Pre-drug and at 30 min
interval for 2.30 h post-drug
No change in
SBP, DBP or HR
(Continued)
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TABLE 1 | Continued
Reference Species Model Dose (CBD) Route Time of CBD
administration
Time of haemodynamic
measurements
Finding
Gomes et al.,
2012
Rats Stress (fear) 15, 30 or 60 nmol BNST Pre-stress Pre-stress and during 10 min
post-stress
30 and 60 nmol:
↓MBP and HR
Martin-Santos
et al., 2012
Human Healthy
volunteers
600mg Oral Pre-test Pre-drug and Hourly interval
for 3 h post-drug
No changes on
BP or HR
Gomes et al.,
2013
Rats Stress (restraint) 15, 30 or 60 nmol BNST Pre-stress Pre-stress and during 60 min
post-stress
Enhanced the
HR increase
post-stress
No changes on
MBP
Pazos et al., 2013 Piglets Hypoxic
ischaemia
1 mg/kg i.v. Post-HI Pre-drug, at 30 and 90 min
post-HI
No changes on
MBP
Gonca and Darici,
2015
Rats Myocardial
infarction
50 µg/kg i.v. Pre-ischaemia Pre-ishaemia At 1, 5 and 11
min post-ischaemia
No changes on
BP or HR
Feng et al., 2015 Rabbits Myocardial
infarction
100 µg/kg i.v. Pre-reperfusion At 15, 30 and 45 min
post-drug
↑ BF
Garberg et al.,
2016
Piglets Hypoxic
ischaemia
1 mg/kg i.v. Post-HI Immediately post HI and at
30, 210 and 570 min post-HI
No changes on
BP or HR
ACSF, Artificial cerebrospinal fluid; BP, blood pressure; BNST, bed nucleus of the stria terminalis; CBD, Cannabidiol; HI, Hypoxic ischemia; HR, heart rate; h, hours; i.p., Intraperitoneal;
i.v., intravenous; MBP, mean blood pressure; MCAO, middle cerebral artery occlusion; min, minutes; SBP, systolic blood pressure.
dogs, rats, piglets, and rabbits (n = 403). Chronic dosing
was assessed in 3 publications in 2 species, including humans
and rats (BP: one study, n = 6; HR: 3 studies, n = 27).
CBD had no effect on BP or HR after acute dosing (BP,
MD 3, 95% CI −1.81, 7.8, p = 0.22; HR, MD −0.05, 95%
CI-2.68, 2.57, p = 0.97, Figures 2A,B) or chronic dosing
(HR MD 0.3, 95% CI −3.97, 4.57, p = 0.89, Figure 3).
Within species analysis revealed that acute CBD dosing
significantly increased HR in rats (p = 0.004, Figure 2B).
Heterogeneity was statistically significant for BP measurements
after acute CBD dosing (p = 0.0006; I2 = 65%) and HR
measurements after chronic CBD dosing (p = 0.05; I2 = 55%;
Figures 2, 3).
Six publications assessed the effect of CBD administration on
BP and HR in models of stress in rats and humans (n = 336).
Overall, CBD administration significantly reduced the increase in
BP (BP, MD:−3.54, 95% CI−5.19,−1.9, p< 0.0001, Figure 4A)
and HR (HR, MD: −16.23, 95% CI −26.44, −6.02, p = 0.002,
Figure 4B) induced by stress. Heterogeneity was statistically
significant in both BP (p < 0.00001; I2 = 73%) and HR (p <
0.00001; I2 = 92%; Figure 4).
Blood Flow
Changes in BF after acute CBD dosing were assessed in 5
publications examining the effects of CBD in models of stroke
or myocardial infarction in 3 species (mice, piglets and rabbits,
n = 56). Overall, CBD had no effects on BF (SMD: 0.58, 95%
CI −0.1, 1.26, p = 0.1). However, subgroup analysis showed
that CBD significantly increased cerebral blood flow (CBF) in
mouse models of stroke (p = 0.009, Figure 5); heterogeneity was
not statistically significant (p = 0.27; I2 = 21%). As only one
study assessed BF after chronic dosing, a meta-analysis was not
applicable.
Route of Administration
We compared differences between local and systemic
administration of CBD on haemodynamics. Local (intracisternal
or intracerebral) administration of CBD was only used in studies
on rats (4 out of 9 studies; 1 under control conditions and 3
under stressful situations). After systemic administration, there
was a significant reduction in HR (p < 0.0001; 2 studies), but
not after local (intracisternal or intracerebral) administration of
CBD (p= 0.11; 3 studies).
CBD Dose-Response on Haemodynamics
The dose-response to CBD was analyzed to establish if there is
a relationship between CBD dose and effect size. Doses ranging
from 0.003 to 22800mg were used in different species of different
models. Overall, there was no relationship between drug dose and
the size of the effect on haemodynamics (BP p = 0.81, HR p =
0.97, BF p= 0.97; Figure 6).
Quality
Among the 25 included publications, 9 publications used
randomisation and allocation concealment in their design,
6 reported blinding assessment of outcome and blinding of
outcome measurements, 20 publications assessed more than one
outcome, 12 conducted dose-response relationships, 19 assessed
a time window for intervention, 4 measured outcomes >24 h
post-drug and 2 publications provided incomplete data due to
subject withdrawal There was no significant relationship between
quality score and any outcome except in BF (Spearman’s rho
coefficient of BP, −0.1, p = 0.54, HR, 0.06, p = 0.66 and BF, 0.87,
p= 0.01).
Publication Bias
Egger‘s test showed no bias present except in studies assessing for
changes in HR in either control or stressful conditions after acute
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FIGURE 2 | Changes in BP (A) and HR (B) induced by acute CBD dosing.
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FIGURE 3 | Changes in HR induced by chronic CBD dosing.
administration of CBD (HR control p= 0.01; HR stress p= 0.049;
Figure 7).
DISCUSSION
The aim of this study was to determine whether CBD alters
haemodynamics in vivo. Our analysis has shown that acute and
chronic dosing of CBD had no effect on BP, HR, or BF under
control conditions. However, in stressful situations, CBD reduces
the increase in MBP and HR observed in rats. Subgroup analysis
revealed that acute CBD administration increases HR in mice
and rats, and increases CBF in mouse models of stroke. Our
analysis has highlighted the limited amount of human research
carried out to date, and suggests that further work is required
to assess the haemodynamic and regional BF impact of acute
and chronic CBD administration in healthy volunteers and
patients.
Overall, our meta-analysis showed that acute and chronic
dosing of CBD had no effect on BP, HR, or BF under control
conditions. However, there was significant heterogeneity with
regards to species and model, dose and route of administration,
and method and time of endpoint measurement (see Table 1)
which makes it difficult to compare studies. It is possible that
species differences may play a role. For example, Bright et al.
found a significant increase in HR and BP with CBD (0.5
and 1mg/kg) in anesthetized dogs (Bright et al., 1974, 1975),
however, no changes were seen with CBD (25mg /kg) in the
HR of anesthetized rabbits (Borgen and Davis, 1974). It is also
worth noting that most of the human data reviewed did not
show any significant effects of CBD while significant effects
were observed in animal studies. The time of cardiovascular
measurements is also very important. For example, in a study
that examined the cardioprotective effect of CBD (50µg/kg
i.v.) in rats showed that BP was significantly reduced post-
CBD treatment compared to control two and a half hours
post-ischaemia (Walsh et al., 2010). However, another study
assessing CBD at the same dose and route of administration on
cardiac arrhythmia (Gonca and Darici, 2015) found no change
in BP, although this was only measured 11min post-ischaemia,
thus any potential later changes in haemodynamics are not
reported. A greater number of homogenous studies are required
to assess the haemodynamic effects of CBD under control
conditions.
Our systematic review has highlighted that there are a
limited number of studies examining changes in regional BF
with CBD, with studies to date only examining changes in
cerebral or myocardial BF. From the limited studies available,
our analysis showed there were no significant changes in
BF overall post-CBD administration. However, in mice and
piglet models of stroke, either intraperitoneal or intravenous
administration of CBD (3 mg/kg or 0.1 mg/kg, respectively)
significantly reduced the infarct volume and increased the
CBF after acute and chronic dosing (Mishima et al., 2005;
Hayakawa et al., 2007a,b; Alvarez et al., 2008). Similarly, in
a rabbit model of myocardial infarction, CBD treatment of
100µg/kg modestly reduced the size of myocardial ischaemic
injury and increased myocardial BF (Feng et al., 2015).
Together, this suggests that further investigation on the effects
of CBD on regional BF, particularly in pathological situations, is
warranted.
There was no relationship found between the dose of CBD
and the effect size. However, in conscious monkeys, toxicology
studies showed that very large doses of CBD (150–300 mg/kg)
caused bradycardia, and CBD doses >200 mg/kg caused heart
failure and death (Rosenkrantz et al., 1981). However, it is worth
noting that this would be equivalent to a dose of 14,000mg in
a 70 kg human. Intracisternal administration of CBD had no
effect on the increase in BP or HR induced by acute restraint
stress in rats while systemic administration did (Granjeiro et al.,
2011). Similarly, no effect was seen in BP after intracerebral
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FIGURE 4 | Changes in BP (A) and HR (B) induced by acute CBD dosing under stressful conditions.
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FIGURE 5 | Changes in regional blood flow induced by acute CBD dosing.
FIGURE 6 | The effect of CBD dose on haemodynamic responses in vivo. The mean difference (MD) in blood pressure (BP, A) or heart rate (HR, B), and
standardized mean difference (SMD) in blood flow (BF, C) is plotted against the log dose (mg) for each study. Error bars represent 95% confidence intervals (CI).
CBD injection in rats (Gomes et al., 2013). This suggests that
systemic administration of CBD is required to observe changes
in haemodynamics.
Although CBD did not affect haemodynamics under control
conditions, our analysis did reveal effects of CBD in pathological
situations. For example, in piglet models of hypoxic injury,
intravenous administration of CBD (0.1 mg/kg) maintained a
stable BP after hypoxic injury compared to control animals
where a reduction in BP was observed (Alvarez et al.,
2008). Also, in rats conditioned to stress (i.e., restraint or
fear), CBD reduced the increase in HR and MBP (Resstel
et al., 2006, 2009; Gomes et al., 2012). However, in mouse
models of stroke there was no significant change in MBP
or HR post-CBD (Mishima et al., 2005; Hayakawa et al.,
2007a, 2008). This suggests that CBD may regulate the
haemodynamics when they are altered at times of stress or acute
illness.
Most of the identified relevant studies were pre-clinical,
and data concerning the effects of CBD on haemodynamics
in humans is limited (n = 36 for BP, n = 87 for HR).
A single oral dose of CBD (320µg/kg, 1mg/kg, 100, 300,
600 or 1200 mg) had no effect on BP or HR in healthy
volunteers under control or stressful situations (Belgrave et al.,
1979; Zuardi et al., 1982, 1993; Gong et al., 1984; Borgwardt
et al., 2008; Bhattacharyya et al., 2009, 2010; Fusar-Poli et al.,
2009; Bergamaschi et al., 2011; Hallak et al., 2011; Winton-
Brown et al., 2011; Martin-Santos et al., 2012). Likewise,
after repeated CBD dosing of 1200mg or 3 mg/kg for 20 or
30 days, respectively there were no apparent effects on HR,
BP, or ECG compared with other treatment groups (Cunha
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FIGURE 7 | Funnel plots for each outcome evaluating publication bias. Standard error (SE) of the mean difference (MD) in blood pressure (BP) and heart rate
(HR), or of the standardized mean difference in blood flow (BF, MD, or SMD, y axes) for each study is plotted against its effect size (horizontal axes). There was
significant bias in HR after acute dosing (B, HR control p = 0.001; E, HR stress p = 0.049).
et al., 1980; Gong et al., 1984). In clinical trials, chronic
administration of CBD 300mg, 10mg/kg or 800mg for 4½
months, 6 or 4 weeks, respectively, incurred no changes on
the ECG, BP, or HR in patients of epilepsy, Huntington or
schizophrenia disorders (Cunha et al., 1980; Consroe et al.,
1991; Leweke et al., 2012). However, repeated oral dosing
of CBD increasing from 100 to 600mg/day over 6 weeks
induced a reduction in standing BP by 10–20 mmHg in
patients with dystonicmovement disorders (Consroe et al., 1986).
Conversely, a single dose of CBD (40mg) given to patients
with intraocular pressure increased systolic BP at 60 and 90
min post-sublingual administration (Tomida et al., 2006). Two
studies of healthy volunteers and patients with social anxiety
disorders showed CBD (400mg) increased cerebral BF on
the left parahippocampal and right posterior cingulate gyrus,
respectively, but not in other brain regions when compared to
control (Crippa et al., 2004, 2011). Bhattacharyya et al. (2010)
suggested that the CBD effects on regional brain function during
multi-tasking may be related to its effects on CBF (Bhattacharyya
et al., 2010). Conversely, Borgwardt et al. (2008) suggested
that the neural effects observed after CBD administration are
unlikely to be a consequence of vascular effects, including CBF
(Borgwardt et al., 2008). Together, this data would suggest that
there are limited haemodynamic effects of CBD in humans,
although further studies where this is the primary endpoint are
warranted based on pre-clinical data reviewed in the present
study.
Limitations
There are several factors that limit the interpretation of the
results of these studies and the understanding of the CBD effects
on haemodynamics. In general, the primary aim of the studies
reviewed was not to assess the haemodynamic effects of CBD.
Some studies did not include an impartial measurement of BP or
HR which may lead to bias in their outcome, or did not state the
method of measurement. Due to the presence of heterogeneity
in publications, outcomes after acute and chronic dosing should
be interpreted with caution. After acute dosing, changes in
haemodynamics at 2 h or the closest time point available to 2
h post-drug were used for analysis, however, depending on the
route of administration, the peak changes in plasma CBD and
therefore associated cardiovascular changes, will be different. In
chronic studies, the length of drug administration also varied. For
the analysis of the relationship between drug dose and effect size,
the total dose up to the time point in which the haemodynamic
was measured was used in the analysis, this also may affect review
conclusions. Only 9 out of 24 publications used randomisation
and 6 reported blinding assessment of outcome, parameters
that should impact on study quality. However, we found no
relationship between quality and effect size. Finally, in some
publications involving comparison of several doses, the number
of animals per control group was divided into the number of
comparison groups to avoid re-counting the same animal more
than once, thus resulting in smaller sample sizes and broader
estimates of the variance.
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CONCLUSION
This meta-analysis and systematic review has highlighted the
haemodynamic effects of CBD administration in vivo. The
positive effects induced by CBD include maintaining the fall in
BP after global hypoxia, reducing the increase in MBP and HR
post-stress, and increasing BF in ischaemia-reperfusion models.
It is possible that beneficial effects of CBD on haemodynamics
occurs when the cardiovascular system is abnormally altered,
suggesting that CBD may be used as a treatment for various
cardiovascular disorders, such as hypertension, myocardial
infarction and stroke. However, the findings from the reviewed
studies were predominately preclinical and significant effects
were only observed in animals. Data from human studies
investigating the effects of CBD on haemodynamics is still very
limited and we suggest that further research in humans under
pathological conditions is required.
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